Diabetes is a m ajor health problem of increasing incidenc e in the United States. Diabetes research has been limited by lack of availability of good animal models, particularly for the study of comorbidities associated with diabetes. We investigated the use of cynomolgu s monkeys as an animal model of both type 1 and type 2 diabetes and compared these naturally occurring diseases with streptozotocin-induced diabetes. Both type 1 diabetics and streptozotocin-induced diabetics present with sudden onset of hyperglyce mia and are ketosis prone without exogenou s insulin. Type 2 diabetics can have a very long period of moderate hyperglyce mia and hypertriglyceridemia and only require exogenou s insulin therapy if pancreati c islet reserves are depleted. Type 2 diabetes is preceded by a relatively long period of insulin resistance that is associated with obesity and dyslipidemia. As insulin resistance progresses, islet size and insulin content increases initially. However, with sustained periods of insulin resistance, islet amyloid polypeptide (IAPP) is deposited in islets and can replace normal islet architecture, resulting in an insulin-de cient state. Appearance of IAPP also occurs in human type 2 diabetics but not in convention al rodent models. Unlike type 2 diabetes, neither type 1 nor streptozotocin-induced diabetes is associated with IAPP. Rather, islets can appear norm al histologically, but have decreased insulin secretion and immunostaining. Further, the am ount of insulin present in the islet is correlated with plasma insulin levels following glucose challenge. Studies are ongoing to determine the pathogenic changes associated with the progression of diabetes and to nd novel drug treatments for diabetics.
INTRODUCTION
A decrease in prevalence of many chronic diseases has occurred since 1980; however, the prevalence of diabetes mellitus has increased (5) . In the United States, there are about 1 m illion people with type 1 diabetes (DM1) and about 15 million with type 2 diabetes (DM 2). The increased prevalence of diabetes is primarily due to an increase in the DM 2 population, which is associated with obesity in 85% of patients (19) . Num erous complications are associated with diabetes, including microvascular disease (eg, retinopathy, neuropathy, and nephropathy) and macrovascular disease. Macrovascular disease is the leading cause of death in diabetics, with increased progression of atherosclerosis resulting in increased coronar y heart disease and stroke (3) .
A m ajor limitation to understanding how diabetes exacerbates atherosclerosis has been the lack of a good animal model of both diabetes and atherosclerosis. Although numerous rodent and rabbit models have been developed to study the pathogenesis of diabetes, these models have not been useful to study changes in plasma lipid param eters and atherogenesis (11, 13) . Diabetes occurs naturally in cynomolgus m onkeys (Macaca fascicularis) (12, 17) and results in changes in plasma lipids and lipoproteins sim ilar to those that occur in hum an diabetics (2, 16) . However, like humans, it takes m any years for these monkeys to develop diabetes. Chem icallyinduced diabetes represents an alternative model. Streptozotocin (STZ), a beta-cell-speci c toxin, has been used in m onkeys, resulting in marked hyperglycemia, dyslipidemia, and, importantly, increased progression of atherosclerosis (9, 10) . The changes associated with STZ have som e properties characteristic of both DM1 and DM 2; however, the changes in pancreatic islets are more characteristic of DM 1.
We report here the pathologic ndings from necropsies of nondiabetic monkeys and from necropsies of monkeys with naturally occurring DM1 and DM 2 and compare these with changes in monkeys with STZ-induced diabetes (STZ-DM). A distinguishing feature of DM 2 is the presence of islet amyloidosis (7, 8, 12) . In contrast, both DM 1 and STZ-DM monkeys have relatively norm al pancreatic islets as indicated by routine histologic examination yet have markedly reduced islet insulin immunostaining. Further, the amount of insulin immunostaining is correlated with in vivo assessments of glucose tolerance (10) . Thus, the cynomolgus monkey appears to be an excellent anim al m odel to study both the pathogenesis of diabetes and the chronic complications of the disease.
METHODS
Clinical records and necropsy exam inations were reviewed from a total of 6,000 cynomolgus monkeys from DIABETES IN CYNOMOLGUS M ONKEYS the Wake Forest University School of Medicine. These monkeys were either part of a breeding colony with a yearly average of approximately 500 -600 monkeys followed from 1977 to 1995 or were involved in experimental research protocols followed to the year 2000. The diagnosis of diabetes was based on an increased fasting glucose concentration. In addition, experimental diabetes was induced in some animals by injecting STZ (Zanosar, Upjohn Co, Kalamazoo, M I; 30 m g/kg intravenously) (10) .
All monkeys were fed ad libitum either an atherogenic diet containing 0.2-0.4 m g of cholesterol/kcal with approximately 40% of calories from fat (10, 17) For experimental purposes, blood samples were collected after an overnight fast. Plasma glucose concentrations were determined by the glucose oxidase m ethod (Glucose Analyzer 2, Beckman Instrum ents, Brea, CA), and insulin concentrations were determined by radioimmunoassay (Incstar, Stillwater, MN) (4, 17) . Fructosamine and glycated hem oglobin concentrations were determined on a Cobas Mira Chem istry Analyzer or by autom ated af nity high-performance liquid chromatography (model CLC-330, Primus Corp, Kansas City, M O), respectively (4, 17) .
Intravenous glucose tolerance tests (IVGTTs) were done by injecting 750 mg/kg of a 50% dextrose solution intravenously (17) . Blood samples were taken at 5 and 0 minutes prior to dextrose injection and then at 5, 10, 20, 30, 40, and 60 m inutes after dextrose injection. The rate of plasma glucose disappearance (K value) was calculated from plasma glucose concentrations from the 5to 20-minute samples, and the area under the curve (AUC) for glucose and insulin was calculated from plasma glucose and insulin concentrations at all time points (10, 17) .
Lipid and lipoprotein m easures were determ ined in total plasma using enzymatic methods and following ultracentrifugation and differential precipitation with dextran sulfate (2) .
Sections of the tail of the pancreas were collected at necropsy, xed in 10% neutral buffered formalin, and processed routinely for light m icroscopy. Five-micrometer-thick paraf n-embedded tissue sections were stained with hematoxylin and eosin for routine histologic examination. Five-m icrom eter-thick deparaf nized sections were imm unostained for the presence of insulin antigen using the primary antibody guinea pig anti-porcine insulin and for the presence of glucagon antigen using the prim ary antibody rabbit anti-porcine glucagon (DAKO, Carpinteria, CA). Eight-micrometer-thick deparaf nized sections were stained with Congo red dye for the presence of amyloid (14) .
RESULTS

Animals and Clinical Assessments
Forty-one m onkeys were identi ed as having naturally occurring diabetes. Of the 41 diabetics, 5 had DM 1 (4 males and 1 fem ale), 31 had DM2 (15 m ales and 16 females), and 5 (1 m ale and 4 females) were not adequately assessed. Fourteen females had been part of the breeding colony; 10 of those 14 had at least 1 offspring, and 6 had gestational diabetes [hyperglycemia rst identi ed during pregnancy (18) ] prior to developing DM 2. One DM 2 monkey died from complications following parturition of a macrosomic infant. One DM2 female was the offspring of a DM2 sire. At the present tim e, 15 DM 2 monkeys are currently alive and part of an experimental protocol.
In general, monkeys were rst identi ed as diabetic by an elevated fasting blood glucose. Norm al fasting glucose concentration for monkeys consuming a chow diet is 62 13 m g/dl and is increased slightly (70 18 m g/dl) when animals consum e an atherogenic diet (4) . Consistent with human ranges reported from the American Diabetes Association (6), we considered any fasting glucose above 126 m g/dl to be abnormal. Fructosamine and glycated hemoglobin levels are also used to identify diabetic anim als and are particularly helpful when adequate fasting is not assured and for assessing antecedent glycemic control (4) . Som e research protocols involved assessment of lipid param eters rather than glycemic param eters, and elevated triglyceride or cholesterol concentrations were noted rst in some monkeys. As previously described (17) , DM2 m onkeys can be hyperglycemic and hypertriglyceridemic but nonketotic for several years before requiring clinical inter vention.
Insulin values were variable and not evenly distributed within the nondiabetic population. The distribution of fasting insulin concentrations is depicted in Figure 1 for 311 cynomolgus monkeys ranging in age from 3 to 21. The median value was 29 U/ml. Insulin values were correlated with animal age (r 0.22, p 0.001) and body mass index (r 0.26, p 0.001). Approxim ately 30% of m onkeys 15 years of age had basal hyperinsulinem ia and/or postprandial hyperinsulinemia.
With the progression from impaired glucose tolerance to diabetes, the monkeys that develop DM2 are initially hyperinsulinem ic, and with time insulin levels drop. These monkeys are typically obese, with body weights and body mass indices outside the 95% con dence intervals for the colony (17) . However, as the glycem ic pro le deteriorates, these monkeys often lose body weight. Although diet restriction and oral agents are useful therapies in these monkeys, exogenous insulin injections are often required. DM2 monkeys can becom e very insulin resistant, with insulin doses ranging from 7 to 300 U daily (approximately 9 U/kg body weight/d). Generally as animals continue to be treated with insulin, they gain more weight and become increasingly insulin resistant. One monkey that has been treated with insulin for 15 years is W AGNER ET AL We have less experience with monkeys characterized as DM 1. These monkeys are not obese upon presentation and require daily exogenous insulin to control hyperglycemia and prevent ketosis. DM1 monkeys are not as insulin resistant as the DM2 monkeys, and exogenous insulin doses range from 6 to 26 U daily (approxim ately 2 U/kg body weight/d).
STZ-DM can result in an insulin-dependent state similar to that of DM1. The extent of islet dam age varies from monkey to monkey, with som e requiring 1 dose of STZ to become hyperglycemic. In m onkeys that are not hyperglycemic, glucose tolerance testing reveals impaired glucose disappearance and decreased insulin response despite relatively norm al fasting glucose concentrations. Thus, depending on the dose, number of injections, and some unknown factors determining susceptibility, monkeys m ay require varying amounts of exogenous insulin. In general, STZ-DM m onkeys are not insulin resistant, and insulin doses for 1 study ranged from 4 to 48 U daily (approximately 1.0 -5.0 U/kg body weight/d) (10) .
Carbohydrate Metabolism
All diabetics have some abnormal glycemic parameters, including increased fasting glucose concentrations, increased glycation of plasm a proteins and hemoglobin, and upon a glucose challenge, delayed glucose clearance. Glucose and insulin responses to a glucose challenge were determ ined in 6 DM2, 3 DM1, and 7 STZ-DM monkeys ( Table 1 ). In addition, IVGTTs were done in the STZ-DM monkeys before induction and in 31 older monkeys ( 15 years) that were age matched with the DM2 monkeys. All diabetic m onkeys had a decreased rate of glucose disappearance (K 1.4) as compared with nondiabetic monkeys (K 2.7). Because of the decreased rate of clearance, the glucose AUC was increased in all types of diabetic m onkeys. The insulin AUC, however, DIABETES IN CYNOMOLGUS M ONKEYS varied with the different types and stages of diabetes. DM1 m onkeys had the lowest insulin response to the glucose challenge followed by STZ-DM monkeys. DM 2 monkeys had, on average, relatively normal insulin AUC due to an average of 2 different responses. Those that had basal hyperinsulinemia have attenuated insulin secretion in response to the glucose challenge, with an insulin AUC roughly the same as that of nondiabetics (51,100 16,790, n 3). Those that had low or normal basal insulin levels also had little response to the insulin challenge, resulting in a reduced AUC (11, 753 883, n 2) comparable to that of DM1 m onkeys. Among nondiabetic animals, younger anim als had lower insulin AUCs than did older m onkeys.
Lipid and lipoprotein measurements were done in a group of 7 DM 2 and 2 DM1 monkeys, and ndings were compared with those from a group of age-matched, nondiabetic m onkeys (n 9) all consum ing the sam e chow diet. DM 1 and DM 2 monkeys had similarly elevated fasting blood glucose values (187 8 and 174 39 mg/dl, respectively) as com pared with controls (68 4 mg/dl). However, glycated hemoglobin levels were m uch higher in DM1 monkeys (17% 0.2%) than in DM 2 m onkeys (9% 1% ); values for both groups were higher than those for nondiabetics (4% 0.3% ). In contrast, total plasm a cholesterol concentrations were higher in DM 2 monkeys than in DM1 and nondiabetic m onkeys ( Figure  2 ). The increase in total cholesterol concentrations in DM2 m onkeys was due to an increase in very low density lipoprotein (VLDL) cholesterol concentrations; there were no differences in low-density lipoprotein (LDL) or high-density lipoprotein (HDL) cholesterol concentrations between DM1 or DM2 monkeys and nondiabetic monkeys. The increase in the triglyceride-rich VLDL particles is consistent with an increase in plasma triglycerides in DM 2 m onkeys (354 121 mg/dl) as compared with DM 1 (125 24 mg/dl) and control (85 13 mg/ dl) monkeys.
Pancreatic Morphology
Pancreatic islets from nondiabetic monkeys differed in size but generally were very cellular, with abundant immunostaining for both insulin ( Figure 3A) and glucagon (not shown). Pancreatic islets from DM1 m onkeys were fewer and smaller than those of nondiabetics. Islets that were present were less cellular, and the cytoplasm appeared lacy. Although very little insulin immunostaining was present ( Figure 3B ), there was abundant glucagon immunostaining (not shown). There was no brosis, inammatory in ltration, or amyloidosis of the islets. Pancreatic islets from DM2 m onkeys ( Figure 3C ) were larger than those from nondiabetic monkeys (12) . Abundant islet amyloidosis was present ( Figure 4) , but there was no in ammation. Islet amyloidosis was con rm ed with Congo red staining, and when examined under polarized light, large areas of apple-green birefringence were observed. Transm ission electron microscopy conrm ed the presence of brillar material typical of amyloid. In addition, previous studies con rmed the presence of speci c islet amylin with positive staining to islet amyloid polypeptide (IAPP) (12) .
The amount of islet amyloid deposition and insulin immunostaining was variable. In Figure 3C , a pancreatic islet is shown for a monkey that had required insulin therapy for 3 years compared with that of a diabetic monkey not yet requiring insulin therapy ( Figure 5 ). The islet of the non-insulin-requiring DM 2 monkey had abundant insulin imm unostaining com pared to with the minim al DIABETES IN CYNOMOLGUS M ONKEYS insulin imm unostaining in a DM 2 m onkey requiring exogenous insulin ( Figure 3C) .
In contrast to islets from DM1 and DM2 m onkeys, islets from STZ-DM monkeys appear normal histologically. However, with immunostaining, islets from STZ-DM monkeys had a marked decrease in insulin staining ( Figure 3D ), ranging from more intense staining in the periphery to virtually no staining, as previously described (10) . Glucagon immunostaining, however, was abundant (not shown).
The degree of islet involvem ent seems to correspond to clinical assessments of glycemic control. Previous studies in the STZ-DM monkeys and age-m atched controls revealed a very strong correlation (r 0.89) between percentage of islet immunostaining and insulin response to an IVGTT (10) . Likewise, in DM2 m onkeys, those with less islet amyloid and m ore intense insulin staining generally were still hyperinsulinemic and did not require insulin therapy. However, once the islets are essentially replaced with amyloid, less insulin staining is discernable and exogenous insulin therapy is required, as with DM 1 monkeys.
DISCUSSION
The clinical signs of hyperglycem ia, increased glycated protein levels, and delayed glucose clearance following an IVGTT support the diagnosis of diabetes m ellitus. Without either longitudinal assessment of descriptive data (body weight, age, etc) and clinical data (presence of hyperinsulinemia, prolonged periods of hyperglycemia and hypertriglyceridemia without ketosis), it is dif cult to differentiate DM1 from more advanced cases of DM2 in monkeys. Anti-islet cell antibodies may be helpful in diagnosing DM 1; however, these antibodies are often only found during the early stages of islet cell destruction (15) .
Although the clinical conditions of DM 1 and DM 2 may appear sim ilar, the pathologic changes are quite different. There are fewer and smaller pancreatic islets in DM1 m onkeys, with very little insulin immunostaining. Also, there is no brosis, in ammatory in ltration (at later stages), or amyloidosis of the islets. Pancreatic islets from DM2 m onkeys, in contrast, are larger and hyperplastic in the early stages of the disease (12) . Islets from early DM 2 monkeys have intense insulin immunostaining, with minimal to moderate amounts of islet amyloid present ( Figure 5 ). Islets from advanced DM 2 monkeys have decreased insulin immunostaining ( Figure 3C ) and are hypocellular, with abundant islet amyloidosis ( Figure  4) . The amyloid has been con rm ed to be almost identical to human IAPP (12) . In contrast, islets from monkeys with STZ-DM appear norm al histologically 6 months after induction. However, with immunostaining, islets from STZ-DM monkeys have a m arked decrease in insulin staining ( Figure 3D) (10) . Although islet insulin immunostaining varied among the different types of diabetic m onkeys, glucagon immunostaining was abundant in all diabetics.
The presence of IAPP has been reported in hum ans, cats, and m onkeys (12) . Rodents and m any other species have differences in the amino acid sequence of 1 region of the protein (residues 20 -29) that is most responsible for the formation of amyloid brils. However, rodents transgenic for the hum an IAPP gene develop islet amyloid and have been used to study the importance of amyloid in the pathogenesis of DM2 (8) . Islet amyloid is found in about 90% of hum an DM 2 cases, and as with monkeys, the degree of islet mass replaced by amyloid appears to be correlated with increasing need for exogenous insulin treatment (7, 8) . We have also found islet amyloid deposition in nondiabetic animals. Little if any amyloid is found in young animals, and increasing amounts of amyloid are found in older, more insulin-resistant animals, but this amount is still less than that found in diabetics (12, 17) . Thus, amyloid deposition precedes overt diabetes. Recent ndings suggest that defects in insulin secretion occur early in the pathogenesis of diabetes (20) . The relationship between early deposition of amyloid and defects in insulin secretion may be an important feature in the progression of DM 2 (8) .
It is dif cult to estim ate the prevalence of naturally occurring diabetes because m any anim als at our facility are terminated for experimental purposes. Regardless, the num ber of DM2 cases was m uch greater than the number of DM1 cases, as is the case in human beings. In addition, gestational diabetes has been described in these m onkeys (18) , and there appears to be a relatively high incidence of DM2 following gestational diabetes. Increased risk of both DM1 and DM 2 and impaired glucose tolerance has been reported in wom en following gestational diabetes (6) .
Lipid and glycemic parameters vary with DM type. Although lipid m easures were only available for 2 DM 1 monkeys, DM1 monkeys had higher glycated hem oglobin concentrations than did DM 2 m onkeys, despite similar fasting glucose concentrations. This increase may be due to som e endogenous production of insulin from the islets of DM2 monkeys that provides additional glycemic control as exogenous insulin doses wear off. It may also be due to higher postprandial glycem ia in DM1 monkeys because of lack of insulin secretion following meals. Although glycated hemoglobin levels are lower in DM 2 monkeys, the plasma triglycerides and total and VLDL cholesterol concentrations are higher. The increase in cholesterol concentrations in diabetics is most often due to impaired lipoprotein lipase activity, resulting in elevated trigly ceride -rich p articles w ith relatively little change in LDL and HDL cholesterol concentrations (1) . Increasing insulin resistance in DM2 monkeys most likely affects lipolytic activity more than in DM 1 m onkeys, which are more insulin sensitive. Although we did not compare plasma lipid responses of STZ-DM monkeys at the same tim e as the DM1 and DM 2 monkeys were assessed, the STZ-DM m onkeys are more like DM1 monkeys in that their plasma lipids and triglycerides are not signi cantly increased as long as their disease is adequately controlled (10) .
One of the m ost important m easures to follow longitudinally is plasma insulin levels. Anim als with borderline diabetes may remain euglycemic for a number of years as a result of compensatory hyperinsulinemia. Even more important than fasting insulin levels is the stimulated insulin response following a glucose challenge. The W AGNER ET AL acute insulin response to a glucose challenge has been shown in people to be impaired years before the development of diabetes (20) . The AUC for insulin is useful for detecting anim als with insulin resistance. Changes in insulin AUC can be seen between young and older nondiabetics despite almost identical glucose AUC (Table 1) . Although glucose AUCs are increased similarly in DM1, DM 2, and STZ-DM monkeys, the insulin AUCs are quite different, with higher levels for DM2 and lower levels for DM 1 m onkeys. Because m onkeys, like hum ans, are one of the few species to develop islet amyloidosis with DM 2, it would be interesting to m easure plasm a amylin concentrations to determine its role in the disease pathogenesis.
With the increased incidence of obesity and diabetes in our aging human population, the monkey m odel is ver y relevant for study of the interactions among aging, obesity, and insulin resistance as well as other associated com orbidities. The pathologic changes in the pancreatic islets are comparable to those seen in hum ans, and the role of impaired insulin secretion from beta cells can be determ ined in relation to increased peripheral insulin resistance. Lipid and lipoprotein m easures are affected similarly in monkeys and humans with diabetes, and thus cardiovascular risk factor intervention studies are quite plausible. Because the num ber of naturally occurring diabetic monkeys may not be suf cient to study som e conditions, such as the increased progression of atherosclerosis with diabetes, STZ-DM monkeys may be useful (9) . Cynomolgus monkeys are a useful anim al model to study both the pathogenesis of the different types of diabetes and som e of the chronic diseases associated with diabetes.
